The estimated Net Worth of John Kiely is at least $2.25 Million dollars as of 10 May 2024. Mr. Kiely owns over 76,453 units of Amneal Pharmaceuticals Inc stock worth over $2,137,878 and over the last 5 years he sold AMRX stock worth over $0. In addition, he makes $112,163 as Independent Director at Amneal Pharmaceuticals Inc.
Sign up
Mr. Kiely AMRX stock SEC Form 4 insiders trading
John has made over 12 trades of the Amneal Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 76,453 units of AMRX stock worth $639,147 on 10 May 2024.
The largest trade he's ever made was exercising 80,128 units of Amneal Pharmaceuticals Inc stock on 9 May 2023 worth over $669,870. On average, John trades about 20,475 units every 91 days since 2019. As of 10 May 2024 he still owns at least 255,727 units of Amneal Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kiely stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Kiely biography
John J. Kiely CPA serves as Independent Director of the Company. Mr. Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. From 1980 to June 2019, he held various roles of increasing responsibility at Pricewaterhouse Coopers, including as U.S. Pharmaceutical Leader and Global Pharmaceutical Assurance Leader. Mr. Kiely is currently and has been since July 2019 on the board of directors of Zovio, Inc., an education technology services company. Mr. Kiely holds a bachelor of science degree from Saint Francis University.
What is the salary of John Kiely?
As the Independent Director of Amneal Pharmaceuticals Inc, the total compensation of John Kiely at Amneal Pharmaceuticals Inc is $112,163. There are 14 executives at Amneal Pharmaceuticals Inc getting paid more, with Andrew Boyer having the highest compensation of $3,113,080.
How old is John Kiely?
John Kiely is 61, he's been the Independent Director of Amneal Pharmaceuticals Inc since 2019. There are 3 older and 18 younger executives at Amneal Pharmaceuticals Inc. The oldest executive at Amneal Pharmaceuticals Inc is Shlomo Yanai, 67, who is the Independent Director.
What's John Kiely's mailing address?
John's mailing address filed with the SEC is C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER, NJ, 08807.
Insiders trading at Amneal Pharmaceuticals Inc
Over the last 7 years, insiders at Amneal Pharmaceuticals Inc have traded over $867,197,480 worth of Amneal Pharmaceuticals Inc stock and bought 3,818,425 units worth $12,997,905 . The most active insiders traders include Gp A, Llcbonderman Davidcou..., Holdings, Llc Aphc, and International Ltd Fosun. On average, Amneal Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $3,857,739. The most recent stock trade was executed by Andrew S Boyer on 14 August 2024, trading 62,711 units of AMRX stock currently worth $491,654.
What does Amneal Pharmaceuticals Inc do?
an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.
What does Amneal Pharmaceuticals Inc's logo look like?
Complete history of Mr. Kiely stock trades at Amneal Pharmaceuticals Inc and Zovio Inc
Amneal Pharmaceuticals Inc executives and stock owners
Amneal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Andrew Boyer,
Executive Vice President - Commercial Operations -
Chintu Patel R.Ph, R.Ph.,
Co-Founder, Co-CEO & Director -
Nikita Shah,
Chief Human Resource Officer, Senior Vice President -
Andrew S. Boyer,
Exec. VP & Chief Commercial Officer of Generics -
Anastasios G. Konidaris,
Exec. VP & CFO -
Joseph Todisco MBA,
Exec. VP & Chief Commercial Officer of Specialty -
Nikita Shah,
Exec. VP and Chief HR Officer & Strategic Planning Officer -
J. Kevin Buchi,
Independent Director -
Ted Nark,
Independent Director -
Emily Alva,
Independent Director -
Gautam Patel,
Director -
Chintu Patel,
Co-Chief Executive Officer, Co-Founder, Director -
Chirag Patel,
President, Co-Chief Executive Officer, Director -
Paul Meister,
Independent Chairman of the Board -
Shlomo Yanai,
Independent Director -
John Kiely,
Independent Director -
Jeffrey George,
Independent Director -
Chintu Patel R.Ph., R.Ph,
Co-Founder, Co-CEO & Director -
Chirag K. Patel,
Co-Founder, Co-CEO, Pres & Director -
Joseph Todisco,
Senior Vice President - Specialty Commercial -
Apurva Saraf,
Senior Vice President - Corporate Development -
Joseph Greer,
Senior Vice President - Global Quality Management -
Stephen Manzano,
Senior Vice President, General Counsel & Corporate Secretary -
Sanjay Jain,
President - India -
Anastasios Konidaris,
Chief Financial Officer, Senior Vice President -
Jason B. Daly Esq.,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Dr. Nikunj Patel,
Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd -
Sanjiv Patel,
Sr. VP of Operations -
Stephen J. Manzano,
Sr. VP, Gen. Counsel & Corp. Sec. -
Anthony DiMeo,
Sr. Director of Investor Relations -
Sheldon Hirt,
SVP, GC & Corp. Sec. -
Jean Selden Greene,
Director -
Holdings, Llc Aphc,
10% owner -
Robert L Burr,
Director -
Bryan M. Reasons,
CFO -
Robert A Stewart,
President and CEO -
Dharmendra Rama,
Director -
Janet S. Vergis,
Director -
Peter R Terreri,
Director -
Paul Bisaro,
Executive Chairman -
David A Buchen,
SVP, Chief Legal Officer -
Todd P. Branning,
SVP and CFO -
Pradeep Bhadauria,
SVP, Chief Scientific Officer -
International Ltd Fosun,
10% owner -
Gustavo Pesquin,
See Remarks -
Gp A, Llcbonderman Davidcou...,
-
Tasos Konidaris,
Executive Vice President & CFO -
Jason B. Daly,
SVP, Chief Legal Officer -
Deborah M. Autor,
Director -
Dipan Patel,
-
Tushar Bhikhubhai Patel,
10% owner